Clinical Trial

Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis

Study acronym: Cellgram-LC
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This phase III clinical trial is designed to evaluate the efficacy and safety of autologous Mesenchymal Stem Cells (MSC) injected hepatic artery.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2020-12-28; most recent amendment 2024-03-20.
Status change: Not Yet Recruiting → Recruiting 2021-08-17
Trial Details
NCT Number NCT04689152
Lead Sponsor Pharmicell Co., Ltd.
Conditions Alcoholic Cirrhosis
Enrollment 200 participants
Start Date 2021-03-02
Primary Completion 2027-08-02 (estimated)
Study Completion 2028-01-02 (estimated)
Updated on ClinicalTrials.gov 2024-03-21